Details of the Drug Reposition

General Information of This Drug (ID: DM1RBYG)

Drug Name
Nitric Oxide   DM1RBYG
Synonyms
Nitric oxide; nitric oxide; nitrogen monoxide; Mononitrogen monoxide; 10102-43-9; nitrogen monooxide; nitrogen protoxide; nitrosyl; Nitrosyl radical; EDRF; CHEBI:16480; endothelium-derived relaxing factor; monoxyde d'azote; oxoazanyl; oxyde azotique; oxido nitrico; Stickstoffmonoxid; Nitric oxide trimer; monoxido de nitrogeno; Stickstoff(II)-oxid; Nitric oxide (JAN); INOmax (TN); oxido de nitrogeno(II); Nitrosoradical; [NO]; oxidonitrogen(); Nitrogen(II) oxide; OHM 11771; AC1L3QHF; Nitric oxide, 985%; DTXSID1020938; CHEMBL1200689; CTK0H7679; ()NO; HNO; INOmax; Nitrosyl; Nitroxyl; Oxoazanyl; Stickmonoxyd; Endogenous Nitrate Vasodilator; Monoxido de nitrogeno; Nitrogen monooxide; Nitrogen monoxide; Nitrosyl hydride; Nitroxide radical; Oxido nitrico; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd [German]; Bioxyde d'azote; Bioxyde d'azote [French]; Endothelium-Derived Nitric Oxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen oxide (NO); Oxide, Nitric; Oxido de nitrogeno(II); Oxidonitrogen(); Vasodilator, Endogenous Nitrate; Nitric Oxide, Endothelium-Derived; Nitrosyl hydride ((NO)H); Endothelium-derived relaxing factor (EDRF)
Therapeutic Class
Bronchodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
5 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Methicillin-resistant staphylococci infection DIS6DRDZ 1A00-1A09 Approved [1]
Hypertension DISLL965 BA00-BA04 Approved [2]
Pulmonary hypertension DIS1RSP5 BB01 Approved [1]
Pneumonia DIS8EF3M CA40 Approved [1]
Respiratory failure DISVMYJO CB41 Approved [3]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 3 [3]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [4]
------------------------------------------------------------------------------------
3 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Persistent fetal circulation syndrome DISSDYEX N.A. Discontinued in Phase 2 [5]
Bronchopulmonary dysplasia DISO0BY5 KB29.0 Discontinued in Phase 2 [6]
Tinea pedis DISWG0OP 1F28.2 Discontinued in Phase 2 [7]
------------------------------------------------------------------------------------

References

1 Nitric Oxide FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207141.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2509).
4 ClinicalTrials.gov (NCT04290858) Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection. U.S. National Institutes of Health.
5 Clinical Trials to Reduce the Risk of Antimicrobial Resistance
6 Midazolam Sedation for Neonatal Lumbar Puncture
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024215)